Recombinant Interferons Beta-1a and Beta-1b: Protein Structural Features and Problematic Issues with Identity Confirmation

Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19

“…The control groups consisted of thirty-nine patients who received only hydroxychloroquine, lopinavir, and ritonavir, or atazanavir-ritonavir. The interferon treated group has decreased the 28 days mortality and increased the 14 days discharge rate among the COVID-19 patients [60,61].…”